Weight gain during and after menopause is one of the most common and frustrating health challenges women face. Research suggests that women gain an average of about one pound per year during this life stage, and for many, standard weight-loss strategies simply stop delivering the results they once did.
Now, a new study points to a combination approach that could significantly improve outcomes for postmenopausal women already using weight-loss medication.
What the new research found
The study, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, examined data from 120 postmenopausal women with overweight or obesity who took tirzepatide the active ingredient in Mounjaro and Zepbound for 12 months or longer. Researchers found that women who paired tirzepatide with hormone therapy lost 35% more weight than those who took the drug on its own.
In practical terms, women in the hormone therapy group lost around 19.2% of their body weight on average, compared to 14% among those on tirzepatide alone. A greater proportion of the hormone therapy group also reached losses of between 20% and 30% of total body weight a threshold that carries well-documented health benefits.
Why the combination may work better
Estrogen plays a significant role in how the body manages energy, distributes fat, and responds to insulin. After menopause, the natural drop in estrogen contributes to increased fat storage particularly around the abdomen along with reduced insulin sensitivity and changes in appetite regulation.
Hormone therapy, which uses estrogen and progesterone to ease menopause symptoms, can partially reverse those metabolic shifts. It may reduce central belly fat accumulation and support better brain signaling around energy balance. Paired with tirzepatide, which independently curbs appetite and improves glucose metabolism, the two treatments may reinforce each other in ways that neither achieves as effectively alone.
There is also a more indirect pathway worth noting. Hormone therapy relieves common menopause symptoms including hot flashes and insomnia two issues that, when left untreated, tend to undermine the lifestyle habits that support weight loss. More restful sleep and fewer disruptive hot flashes make it easier to exercise regularly and make consistent, healthier food choices alongside any medication.
Could other weight-loss drugs produce the same effect?
Doctors believe this benefit likely extends beyond tirzepatide. Why combining these 2 treatments crushes post menopause weight gain. The broader class of GLP-1 receptor agonists which includes semaglutide, sold as Ozempic and Wegovy may produce similar results when combined with hormone therapy. A 2024 study of 106 postmenopausal women published in the journal Menopause found that those who took semaglutide with hormone therapy were more likely to lose between 5% and 10% of their body weight after 12 months compared to those on semaglutide alone.
Side effects worth knowing
Both treatments carry potential side effects. The most commonly reported issues with tirzepatide, per the U.S. Food and Drug Administration, include nausea, diarrhea, vomiting, constipation, fatigue and hair loss. Hormone therapy side effects vary by formulation but, according to the American College of Obstetricians and Gynecologists, can include vaginal spotting, temporary breast soreness, bloating and headaches, with spotting typically resolving within six months.
Experts note that taking both medications together is considered safe based on current data, though comprehensive safety information on the specific combination remains limited.
The bigger picture for women managing menopause weight gain
These findings underscore that weight management after menopause is not straightforward, and hormonal status plays a measurable role in how the body responds to treatment. A personalized approach that accounts for that reality may produce meaningfully better results.
For women who have struggled to lose weight during or after menopause, speaking with a healthcare provider about whether hormone therapy makes sense alongside a GLP-1 medication is a practical and worthwhile conversation to have.
